Results 151 to 160 of about 9,624 (181)
Some of the next articles are maybe not open access.
HIF2α Antagonism Has Antitumor Activity in Advanced ccRCC
Cancer Discovery, 2018Abstract The HIF2α antagonist PT2385 achieved responses in 14% of patients with heavily pretreated ccRCC.
openaire +2 more sources
ccRCC–adipose crosstalk in disease pathogenesis
Nature Reviews Nephrology, 2021openaire +2 more sources
Belzutifan: A Breakthrough in Targeted Therapy for ccRCC
Theoretical and Natural ScienceBelzutifan, a novel orally bioavailable small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α), represents a mechanistically distinct and clinically promising therapy for clear cell renal cell carcinoma (ccRCC), particularly in patients with von Hippel–Lindau (VHL) disease.
openaire +1 more source
Hijacking the vasculature in ccRCC—co-option, remodelling and angiogenesis
Nature Reviews Urology, 2013The most common type of malignancy in the adult kidney is clear cell renal cell carcinoma (ccRCC), for which antiangiogenic therapy with surgery is currently the standard treatment. Although overall survival of patients with metastatic ccRCC has been substantially extended by antiangiogenic therapy with agents such as sorafenib and sunitinib, patients ...
openaire +2 more sources
HIF-2α-Induced Upregulation of CD36 Promotes the Development of ccRCC
Experimental Cell Research, 2022Xiaoqing Luo, Anhua Xiao, Enze Zheng
exaly
Exploratory treatment options fail in ccRCC
Medicom Conference Report ASCO 2022, 2022Thomas Powles, Robert van den Heuvel
openaire +1 more source
DUSP4 Promotes the Carcinogenesis of CCRCC via Negative Regulation of Autophagic Death.
Bioscience, Biotechnology and Biochemistry, 2021Xianxin Zhu
exaly